A recent study confirms that hybrid closed-loop (HCL) insulin delivery systems outperform traditional insulin therapies in controlling blood sugar levels for people with type 1 diabetes. Also called artificial pancreases and automated insulin delivery systems, these wearable systems combine an insulin pump, a continuous glucose monitor, and a computer algorithm that automatically adjusts insulin delivery in real time.

The study looked at the results of 28 clinical trials and found HCL systems increased time in range by an average of 10.9 to 21.6 percentage points compared with traditional insulin therapy. They also reduced time spent in dangerously low blood sugar levels, helping to lower the risk of hypoglycemia.

Is an HCL System Right for You?

Unlike traditional insulin therapy, which requires constant manual adjustments, HCL systems automate much of the work, reducing fluctuations and making diabetes management easier. They can be especially useful for people struggling with blood sugar highs and lows.

However, HCL systems can be expensive and require insurance approval. They may also be challenging for those less comfortable with technology. They require users to enter meal data and make occasional manual adjustments.

If it’s difficult for you or a loved one to keep glucose levels under control, a healthcare provider can help you explore treatment options. They can help weigh the pros and cons of different approaches based on your individual needs, lifestyle, and insurance coverage.

Learn more about treatment options for keeping glucose levels in check for type 1 diabetes.

Find Your Team

On myT1Dteam, the social network for people living with type 1 diabetes and their loved ones, members come together to ask questions, give advice, and share their stories with those who understand life with type 1 diabetes.

Have you tried a hybrid closed-loop system? What’s been your experience? Share your experience in the comments below, or start a conversation by posting on your Activities page.